How HDAC11 affects the immune response to cancer
Regulation of anti-tumor immunity by HDAC11
This study is looking at how a protein called HDAC11 affects the immune system's ability to fight cancer, and it hopes to find ways to boost the immune response in patients by blocking this protein, which could lead to better cancer treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | George Washington University NIH-funded |
| Lab location | 1 site (Washington, United States) |
| Project ID | NIH-10977315 on NIH RePORTER |
What this research studies
This research investigates the role of HDAC11 in regulating the immune system's ability to fight cancer. It focuses on how inhibiting HDAC11 can enhance the production of pro-inflammatory cytokines and improve the anti-tumor response in immune cells, particularly T lymphocytes and neutrophils. By studying mouse models, the research aims to uncover the mechanisms through which HDAC11 influences tumor immunity and could lead to more effective cancer treatments. Patients may benefit from insights gained about how to enhance their immune response against tumors.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with cancers that may respond to immunotherapy, particularly those with conditions where HDAC inhibitors are being considered.
Not a fit: Patients with cancers that do not involve the immune system or are not responsive to immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that improve the effectiveness of cancer immunotherapy.
How similar studies have performed: Other research has shown promising results with HDAC inhibitors in cancer treatment, suggesting that this approach may lead to significant advancements in immunotherapy.
Where this research is happening
Washington, United States
- George Washington University — Washington, United States (Active)
Researchers
- Principal investigator: Seto, Edward — George Washington University
- Study coordinator: Seto, Edward
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.